Australia's CSL Gets TGA Green Light For Swine Flu Vaccine; Donates 10 Percent Of Supply To WHO
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - One week after CSL announced that one dose of its swine flu vaccine Panvax was effective in staving off the A/H1N1 virus, the company received the green light from Australia's Therapeutic Goods Administration to register the product in Australia for use in people older than 10 years of age
You may also be interested in...
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL's Seasonal Flu Vaccine Halted In Kids Under 5 Following Spike In Adverse Events In West Australian Children
PERTH, Australia - Australia's Therapeutic Goods Administration is investigating reports of an increase in adverse events tied to CSL's seasonal flu vaccine in Western Australia in children under the age of five
CSL Releases First Corporate Responsibility Report; Highlights Access To Medicines, Environmental Impact And Compliance
PERTH, Australia - Melbourne-headquartered CSL March 29 released its first Corporate Responsibility Report, combining information about the company's economic, social and environmental performance for 2009